The first Phase III data presented for Merck & Co. Inc.'s new varicella zoster vaccine V212 show that it can prevent shingles and reduce pain and other complications of the virus in recipients of autologous hematopoietic stem cell transplants (auto-HSCT). Another Phase III trial in subjects with malignancies is ongoing.
Merck & Co already markets the live attenuated virus vaccine, Zostavax, for the prevention of herpes zoster (shingles) in individuals...







![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)